Biocon Limited , a leading biopharmaceutical company, has announced the early redemption of Non-Convertible Debentures (NCDs) worth Rs 1,070.00 crore, demonstrating the company's strong financial position and commitment to optimizing its debt structure.

Early Redemption Details

The Board of Directors of Biocon Limited approved the early full redemption of 107,000 unlisted, secured, rated, redeemable Non-Convertible Debentures during a meeting held on October 1, 2025. These NCDs, each with a face value of Rs 1.00 lakh, were originally issued on February 21, 2023.

Financial Implications

The total value of the redeemed NCDs amounts to Rs 1,070.00 crore, showcasing Biocon's ability to manage its financial obligations effectively. This move is likely to improve the company's debt profile and potentially reduce interest expenses.

Completion of Payment

Biocon has successfully completed the payment to debenture holders and the debenture trustee for the early redemption. This prompt action underscores the company's liquidity and financial prudence.

Board Meeting Details

The Board meeting that approved this significant financial decision was conducted on October 1, 2025, lasting from 6:30 PM to 6:48 PM IST. The swift decision-making process reflects the company's efficient governance practices.

Market Impact

While the immediate market reaction to this news remains to be seen, the early redemption of such a substantial amount of debt instruments typically signals financial strength and could be viewed positively by investors and market analysts.

Regulatory Compliance

In line with regulatory requirements, Biocon has duly informed the stock exchanges about this development, ensuring transparency and compliance with the SEBI Listing Regulations, 2015.

This strategic financial move by Biocon Limited demonstrates the company's proactive approach to debt management and its robust financial health, which could potentially enhance investor confidence in the biopharmaceutical giant's fiscal strategies.

Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., has announced a significant milestone in its expansion into the U.S. pharmaceutical market. The company has secured approval dates for its denosumab biosimilars, Bosaya™ and Aukelso™, marking a crucial step in its strategy to broaden access to advanced biologic medicines.

Settlement Agreement Clears Path for Commercialization

BBL has reached a settlement and license agreement with Amgen Inc., resolving pending patent litigation at the United States District Court for the District of New Jersey. This agreement paves the way for Biocon Biologics to launch Bosaya™ and Aukelso™ in the U.S. market from October 1, 2025.

About the Biosimilars

Bosaya™ and Aukelso™ are biosimilar versions of Amgen's Prolia® and Xgeva®, respectively. These products are used in the treatment of osteoporosis and cancer-related bone conditions:

• Bosaya™: A 60 mg/mL injection in a single-dose prefilled syringe (PFS)
• Aukelso™: A 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial

FDA Approval and Interchangeability

The U.S. Food and Drug Administration (FDA) approved both Bosaya™ and Aukelso™ in September 2025. Notably, the FDA also granted provisional interchangeability designation for both biosimilars, potentially enhancing their market position.

Treatment Applications

Bosaya™ Indications

• Treatment of postmenopausal women with osteoporosis at high risk for fracture
• Increasing bone mass in men with osteoporosis at high risk for fracture
• Treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture
• Increasing bone mass in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
• Increasing bone mass in women receiving adjuvant aromatase inhibitor therapy for breast cancer

Aukelso™ Indications

• Prevention of skeletal-related events in patients with multiple myeloma and bone metastases from solid tumors
• Treatment of adults and skeletally mature adolescents with giant cell tumor of bone
• Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy

Market Impact and Company Strategy

Shreehas Tambe, CEO & Managing Director of Biocon Biologics, emphasized the significance of this development: "This settlement paves the way for Biocon Biologics to bring our high-quality denosumab biosimilars, Aukelso™ and Bosaya™, to patients and healthcare providers in the United States. These therapies will not only strengthen our oncology portfolio but also mark our entry into the bone health space—an important step as we continue to broaden access to life-changing biologics for patients across therapeutic areas."

Market Potential

The introduction of these biosimilars addresses significant health concerns in the U.S.:

Conclusion

Biocon Biologics' successful entry into the U.S. market with Bosaya™ and Aukelso™ represents a significant step in the company's global expansion strategy. By providing more affordable alternatives to established treatments for osteoporosis and cancer-related bone conditions, Biocon Biologics aims to improve patient access to critical therapies while strengthening its position in the competitive biosimilars market.